ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen

May 20, 2020
Alex Delaney-Gesing

Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.

 

See more ASCRS conference coverage here 

Related Content:

ASCRS | News